PharmaCielo Reports Q4 2024 Financial Results
PharmaCielo (PCLOF) reported strong Q4 2024 financial results, achieving 143% year-over-year sales growth with total revenue of $3.54 million for the year. The company's Q4 net revenue reached $1.1 million, more than triple compared to the same period last year.
Key financial improvements include significant cost reductions: office and general expenses decreased by $591,000, salaries by $1,189,000, and marketing costs by $428,000. The company's Adjusted EBITDA improved by $1.1 million versus last year.
PharmaCielo announced plans to issue up to 5 million common shares to settle approximately $500,000 in debt owed to service providers, former employees, and directors. The company expects to achieve positive EBITDA and cash flow in 2025, with sales projected to accelerate in the latter half of the year.
PharmaCielo (PCLOF) ha riportato risultati finanziari solidi per il quarto trimestre del 2024, raggiungendo una crescita delle vendite del 143% rispetto all'anno precedente con un fatturato totale di 3,54 milioni di dollari per l'anno. Il fatturato netto del quarto trimestre dell'azienda ha raggiunto 1,1 milioni di dollari, più del triplo rispetto allo stesso periodo dell'anno scorso.
I principali miglioramenti finanziari includono significative riduzioni dei costi: le spese generali e di ufficio sono diminuite di 591.000 dollari, gli stipendi di 1.189.000 dollari e i costi di marketing di 428.000 dollari. L'EBITDA rettificato dell'azienda è migliorato di 1,1 milioni di dollari rispetto all'anno precedente.
PharmaCielo ha annunciato piani per emettere fino a 5 milioni di azioni ordinarie per saldare circa 500.000 dollari di debiti dovuti a fornitori di servizi, ex dipendenti e amministratori. L'azienda prevede di raggiungere un EBITDA positivo e un flusso di cassa nel 2025, con vendite che si prevede accelereranno nella seconda metà dell'anno.
PharmaCielo (PCLOF) reportó resultados financieros sólidos para el cuarto trimestre de 2024, logrando un crecimiento en ventas del 143% interanual con ingresos totales de 3.54 millones de dólares para el año. Los ingresos netos del cuarto trimestre de la compañía alcanzaron 1.1 millones de dólares, más de tres veces en comparación con el mismo período del año pasado.
Las principales mejoras financieras incluyen reducciones significativas de costos: los gastos de oficina y generales disminuyeron en 591,000 dólares, los salarios en 1,189,000 dólares y los costos de marketing en 428,000 dólares. El EBITDA ajustado de la compañía mejoró en 1.1 millones de dólares en comparación con el año pasado.
PharmaCielo anunció planes para emitir hasta 5 millones de acciones comunes para saldar aproximadamente 500,000 dólares en deudas con proveedores de servicios, ex empleados y directores. La compañía espera lograr un EBITDA positivo y flujo de caja en 2025, con ventas proyectadas para acelerar en la segunda mitad del año.
PharmaCielo (PCLOF)는 2024년 4분기 강력한 재무 실적을 보고하며, 전년 대비 143%의 매출 성장을 달성하고 연간 총 수익이 354만 달러에 달했습니다. 회사의 4분기 순수익은 110만 달러에 도달했으며, 이는 지난해 같은 기간에 비해 세 배 이상 증가한 수치입니다.
주요 재무 개선 사항으로는 비용 절감이 포함됩니다: 사무실 및 일반 경비가 59만 1천 달러, 급여가 118만 9천 달러, 마케팅 비용이 42만 8천 달러 감소했습니다. 회사의 조정 EBITDA는 지난해에 비해 110만 달러 개선되었습니다.
PharmaCielo는 서비스 제공자, 전 직원 및 이사에게 약 50만 달러의 부채를 정산하기 위해 최대 500만 주의 보통주를 발행할 계획을 발표했습니다. 회사는 2025년까지 긍정적인 EBITDA와 현금 흐름을 달성할 것으로 예상하며, 판매는 올해 하반기에 가속화될 것으로 예상됩니다.
PharmaCielo (PCLOF) a annoncé de solides résultats financiers pour le quatrième trimestre 2024, réalisant une croissance des ventes de 143 % par rapport à l'année précédente avec un chiffre d'affaires total de 3,54 millions de dollars pour l'année. Le chiffre d'affaires net du quatrième trimestre de l'entreprise a atteint 1,1 million de dollars, soit plus de trois fois celui de la même période l'année dernière.
Les principales améliorations financières incluent des réductions de coûts significatives : les frais de bureau et généraux ont diminué de 591 000 dollars, les salaires de 1 189 000 dollars et les coûts marketing de 428 000 dollars. L'EBITDA ajusté de l'entreprise a progressé de 1,1 million de dollars par rapport à l'année précédente.
PharmaCielo a annoncé des plans pour émettre jusqu'à 5 millions d'actions ordinaires afin de régler environ 500 000 dollars de dettes envers des prestataires de services, d'anciens employés et des administrateurs. L'entreprise s'attend à atteindre un EBITDA positif et un flux de trésorerie en 2025, avec des ventes qui devraient s'accélérer dans la seconde moitié de l'année.
PharmaCielo (PCLOF) hat starke Finanzzahlen für das 4. Quartal 2024 gemeldet und ein Umsatzwachstum von 143% im Vergleich zum Vorjahr erzielt, mit einem Gesamtumsatz von 3,54 Millionen Dollar für das Jahr. Der Nettoumsatz des Unternehmens im 4. Quartal erreichte 1,1 Millionen Dollar, mehr als das Dreifache im Vergleich zum gleichen Zeitraum des Vorjahres.
Wesentliche finanzielle Verbesserungen umfassen signifikante Kostensenkungen: Büro- und allgemeine Ausgaben sanken um 591.000 Dollar, Gehälter um 1.189.000 Dollar und Marketingkosten um 428.000 Dollar. Das bereinigte EBITDA des Unternehmens verbesserte sich um 1,1 Millionen Dollar im Vergleich zum Vorjahr.
PharmaCielo kündigte Pläne an, bis zu 5 Millionen Stammaktien auszugeben, um etwa 500.000 Dollar an Schulden gegenüber Dienstleistern, ehemaligen Mitarbeitern und Direktoren zu begleichen. Das Unternehmen erwartet, 2025 ein positives EBITDA und einen positiven Cashflow zu erreichen, wobei die Verkaufszahlen in der zweiten Jahreshälfte voraussichtlich anziehen werden.
- 143% year-over-year revenue growth to $3.54M
- Q4 revenue tripled year-over-year to $1.1M
- Adjusted EBITDA improved by $1.1M vs previous year
- Cost reductions totaling over $2.2M
- Additional working capital needed for operations
- Dilution from 5M share issuance for debt settlement
- Still not EBITDA positive
- PharmaCielo achieved
143% Year-Over-Year Sales Growth, Generating Year-to-Date Q4 Total Revenue of$3.54 Million . - Revenues and Gross Profit Margin Increased with More Diverse Customer Base.
- Q4 Cash Flow Continued to Improve and Adjusted EBITDA Increased by
$1.1 Million versus Last Year Reflecting Strong Sales Growth and Reduced Costs. - Financial Year-End is March 31. Audited Financial Statements will be for the Fifteen-Month Period from January 1, 2024, to March 31, 2025.
Toronto, Ontario and Rionegro, Columbia--(Newsfile Corp. - February 28, 2025) - PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) ("PharmaCielo" or the "Company"), a global cannabis products company and Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, today reported significant financial and operational progress for the three and twelve months ended December 31, 2024. All figures presented in this press release are reported in Canadian dollars, unless otherwise specified.
"Throughout 2024, PharmaCielo delivered robust revenue growth by strategically expanding into new international markets while maintaining rigorous cost discipline. These complementary initiatives have considerably strengthened our financial foundation," commented Marc Lustig, Chairman and CEO of PharmaCielo. "With a diversified product portfolio that now reaches beyond CBD isolate, we are well-positioned to meet the evolving needs of our global customer base and maintain strong revenue momentum."
Mr. Lustig added, "Over the past four quarters, we have steadily advanced toward breakeven Adjusted EBITDA. We are entering 2025 from a position of strength, with no major capital investments required to achieve full commercial capacity. Our momentum points to positive EBITDA and cash flow ahead, with sales expected to gain velocity in the latter half of the year."
Summary Financials - Fourth Quarter Ended December 31, 2024
| Three Months Ended | Twelve Months Ended | |||
| (000's) | December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 |
| Revenue | ||||
| Gross Profit (Loss) | ||||
| Adjusted EBITDA | ||||
| Net Loss | ||||
| Net Loss per Share | ||||
*Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The term Adjusted EBITDA does not have any standardized meaning under IFRS. Therefore, it may not be comparable to similar measures presented by other companies.
PharmaCielo has achieved substantial revenue growth, recording
Strategic Cost Optimization and Operational Efficiencies
PharmaCielo continues to drive financial discipline, achieving substantial cost reductions while optimizing its operations for long-term growth. Compared to 2023, the Company reduced office and general expenses by
Additionally, PharmaCielo has streamlined its operations, right sized its cultivation capacity, and eliminated non-essential expenditures, creating a leaner and more agile organization. These initiatives have significantly strengthened the Company's financial position, aligning resources to maximize growth opportunities and ensuring sustainable success.
Positive Outlook for 2025
With a strong sales pipeline, rising revenues, and ongoing cost reductions, PharmaCielo is on track to achieve positive cash flow and profitability in 2025. The Company's first-mover advantage in Colombia, combined with its advanced cultivation and scientific processing capabilities, positions it to capitalize on the expanding global demand for medicinal cannabis.
To support its growing sales pipeline and increased revenues, PharmaCielo will require additional working capital. This need will be met through a private placement, with the majority of the investment coming from insiders and existing shareholders, demonstrating their confidence in the Company's long-term growth trajectory.
"As we move into 2025, we are excited about the opportunities ahead," added Mr. Lustig. "Our operational efficiencies, strong product portfolio, and expanding global footprint set the stage for a transformative year. We are committed to delivering sustained value to our shareholders and solidifying PharmaCielo's position as a global leader in the medicinal cannabis industry."
For further detailed information and analysis, please see the financial statements and management's discussion and analysis for the period ending December 31, 2024, as posted at sedarplus.ca and pharmacielo.com.
Shares for Settlement of Certain Amounts Owing
Today, the Company announced that it intends to issue, subject to the approval of TSXV, up to 5,000,000 common shares of the Company ("Settlement Shares"), in satisfaction of up to
About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medical dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.
The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location plays in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
For further information
Ian Atacan, Chief Financial Officer
i.atacan@pharmacielo.com
Media and Investor Inquires:
investors@pharmacielo.com
Forward-Looking Statements
This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements in this news release include, without limitation, statements regarding the issuance of the debenture units, including the timing and completion of any future issuances thereof.
The forward-looking statements in this news release are necessarily based on assumptions, including assumptions with respect to PharmaCielo's ability to obtain necessary approvals for the issuance of the debenture units.
Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic instability relating to COVID-19 or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242782
FAQ
What was PharmaCielo's (PCLOF) revenue growth in Q4 2024?
How much cost reduction did PharmaCielo achieve in 2024?
What is PharmaCielo's debt settlement plan for 2025?
When does PharmaCielo expect to achieve positive EBITDA?
